Rapid Initiation of HIV Antiretroviral Treatment (RIA)
Antonio E. Urbina, MD
Professor of Medicine, Icahn School of Medicine
Medical Director, Institute for Advanced Medicine
Mount Sinai Hospital New York, New York
Videos of live meetings of PRN in NYC are owned and published by Physicians’ Research Network, Inc. Copyright © 2022. All rights reserved.
Please note: Since we created this presentation, New York State updated its Rapid ART guidelines. “Clinicians should offer rapid initiation of ART—preferably on the same day or within 72 hours—to all individuals who are candidates for rapid ART initiation and who have a confirmed HIV diagnosis or a reactive HIV screening result pending results of a confirmatory HIV test or suspected acute HIV infection, i.e., HIV antibody negative and HIV RNA positive.” This presentation includes the outdated recommendation of 96 hours.
Dr. Antonio E. Urbina is the Medical Director for the Mt. Sinai Institute for Advanced Medicine Downtown clinic in New York City. Dr. Urbina is a Professor of Medicine at the Icahn School of Medicine at Mount Sinai and serves as Medical Director for the Clinical Education Initiative of the New York State Department of Health (DOH) AIDS Institute. Since completing his residency in Internal Medicine at Saint Vincent Catholic Medical Center in Manhattan, Dr. Urbina has pioneered innovative educational programming for community-based clinics, hospitals, and public health departments. He has directed more than 10 HIV clinical trials research protocols and serves on the NYS DOH AIDS Institute Clinical Guidelines Committee. From 2007 to 2009, Dr. Urbina served on the Presidential Advisory Council on HIV/AIDS (PACHA) and from 2014 to 2015 served on Governor Cuomo’s Task Force to end the AIDS epidemic in New York State.
At the completion of this educational session, participants will:
1. Understand the evidence that supports the need for early diagnosis and linkage to care of people with HIV infection.
2 .Know how to identify safe and efficacious rapid ART regimens based on known patient characteristics, as well as regimens to avoid.
3. Be able to address treatment barriers to providing rapid ART to all patients in HIV care.
Policies and standards of the Medical Society of the State of New York and the Accreditation Council for Continuing Medical Education require that speakers and planners for continuing medical education activities disclose any relevant financial relationships they may have with commercial interests whose products, devices, or services may be discussed in the content of a CME activity.
- Dr. James F. Braun, DO (Course Director) has no relevant financial relationships to disclose.
- Dr. William M. Valenti (Moderator) has no relevant financial relationships to disclose.
- Dr. Antonio E. Urbina (Presenter) has had the following personal financial relationships in the past 24 months with manufacturers of the products or services that may be presented in this CME activity: Consultant to Janssen; Sponsored Research from Gilead; Scientific Advisory Panelist for ViiV, Merck, and Gilead. Dr. Urbina submitted their slides in advance for adequate peer review, and will support their presentation and clinical recommendations with the best available evidence from the medical literature. All relevant financial relationships have been mitigated.
Download Article PDF/Slides